The aim of this Challenge is to develop an in vitro assay that can reliably evaluate tumourigenicity of human engineered T cell therapies (primary and/or induced pluripotent stem cell (iPSC) -derived) and that could potentially be applied to multiple immune cell types (e.g. NK or B cells).
Challenges briefing webinar
View the Challenges briefing webinar to find out more about this Challenge. A summary of the Q and A session with the Sponsors is available in the Full Challenge information below.
Cell therapies are medical treatments where viable cells are grafted into a patient to achieve a therapeutic effect, such as replacing damaged tissue or regaining lost functionality. Engineered T cells expressing a chimeric antigen receptor (CAR-T) are cell therapies capable of targeting cancer cells via cell-mediated immunity – they are proving to be effective therapeutic approaches for some cancers, such as haematologic cancers, in patients who have not responded to traditional therapies. There are currently six FDA approved CAR-T cell therapies, including two of the first anti-CD19 CAR-T therapies, Kymriah and Yescarta, that have a potential target population of 10,000 patients in the USA alone.
Types of T cell therapies
Genetically engineered T cells for therapeutic use include CAR-T cells and TCR-T cells. TCR-T cells are T cells engineered to express a T cell receptor (TCR) that recognises a peptide antigen only when loaded within a specific human leukocyte antigen protein. CAR-T cells or TCR-T cells can also be either effector T cells, in the case of oncology applications, or regulatory T cells (Tregs) developed to treat autoimmune or inflammatory conditions. Effector T cells generally serve to eliminate antigen-positive cells (such as tumour cells) and promote an inflammatory environment, whereas Tregs – used in autoimmune and inflammatory diseases – dampen inflammation through bystander suppression mechanisms. Antigens recognised by CAR- or TCR-T cells are typically over-expressed in diseases (e.g. tumour-associated antigens), making them robust targets for therapies.
Generation of T cell therapies
Engineered T cell products can be manufactured from the patient’s own cells (autologous) or from healthy donors (allogeneic) generated either from primary T cells or derived from iPSCs. Generation of specific types of CAR- or TCR-T cells is achieved through expansion of the chosen cell type or through forced lineage commitment. The T cell products can then be further engineered to express cytokine receptors or to secrete cytokines or antibody-like proteins – known as armoured T cells to achieve their desired therapeutic effect. For allogenic products, further genetic manipulation (e.g. inactivation/elimination of donor TCR) is required to prevent graft versus host disease (GVHD).
Potential risks with T cell therapies
Although viral transduction of primary differentiated T cells has not been directly associated with leukaemia transformation to date, processes using genetic manipulation in the generation of T cell therapies can all present a risk of cell transformation and tumourigenicity which needs to be investigated . There are a number of factors that could drive cell transformation, including:
- Random integration (and potential insertional mutagenesis) of the viral vector or transposon used for transgene delivery.
- Introduction of unintended alterations to the genome (e.g. point mutations, deletions, inversions and translocations) from further modification of the T cells performed with designer nucleases (e.g. zinc fingers, TALEN or CRISPR/Cas9).
Off-target genome editing through the introduction of mutations that may lead to tumourigenicity or uncontrolled cell growth presents a key safety concern. Recently, two clinical cases of CAR-T derived lymphoma have been reported, resulting in the death of one patient and the clinical trial withdrawal [2, 3].
The current approaches to evaluate T cell transformation and tumourigenicity concerns are limited. In silico and molecular biology assays can identify viral insertions, mutations, or translocations, but their interpretation needs to be linked to functional assays that directly assess cell transformation or tumourigenicity. The conventional approach for tumourigenicity testing is based on the in vivo tumourigenicity assay, where cells are implanted at an ectopic site (e.g. subcutaneously, under the kidney capsule or testis capsule) in immunodeficient mice and which are then monitored for the formation of tumour masses. These studies are limited in their value, primarily due to a lack of scientific consensus on the selection of the most relevant animal models to evaluate tumourigenic potential and how predictive these models are of clinical outcome.
The tumourigenic potential of cell therapy products manufactured from mature human T cells can be evaluated in vitro using the cytokine-independent growth assay. This assay is based on the principle that lymphocyte growth and survival are dependent on common gamma chain cytokines, which include Interleukin (IL)-2, IL-7, and IL-15 [4, 5, 6]. Lymphocyte growth in the absence of these cytokines is used as an indicator of cellular transformation and can help inform tumourigenicity risk assessment. While the cytokine-independent growth assay may be useful for the identification of potential hazards, it has a number of limitations. These include the absence of relevant positive controls that mimic cell transformation of the T cell product, undefined sensitivity (currently only technically assessed using cell lines), and lack of a standardised protocol. Mature T cell leukaemia and lymphomas are also highly heterogeneous, and not all these neoplasms do exhibit growth in the absence of cytokines [7, 8]. The cytokine-independent growth assay also failed to predict the recent documented CAR-T derived lymphoma cases [2, 3].
A robust, in vitro assay (or suite of assays) capturing key characteristics of transformed T cells is required to support and complement the interpretation of in silico and molecular assays for robust assessment of potential T cell transformation, with the aim of replacing in vivo studies and preventing T cell therapy-derived leukaemia in patients.
There are over a thousand (mainly CAR-T) T cell-based therapies currently in clinical trials  and many more are at the preclinical stage of development. While the relevance of the use of mice to assess modified T cell tumourigenicity potential is debatable, in vivo studies are sometimes requested by regulatory authorities. In vivo studies to assess tumourigenicity of modified T cells involve a minimum of 30 to 40 immunocompromised mice and can run from six to 12 months in duration. However, the standard in vivo experiment using NOD SCID gamma (NSG) mice is ill-suited to detect human tumourigenic T cells, as xenogeneic GVHD appears within a few weeks resulting in termination of the study before tumourigenic events, which may take months to develop, can be detected. Even in models where GVHD is delayed or mitigated, such as the MHCI/II knockout mice or humanised mice , the GVHD will still occur during the six to 12 months required for a complete tumourigenicity study. As a result, large numbers of animals are needed to compensate for those euthanised due to the appearance of GVHD.
Specific constructs such as lentiviruses over-expressing NPM-ALK can potentially generate tumours within weeks . However, animal models may not provide an appropriate physiological environment to allow most types of human-engineered T cells to persist, which may explain why no CAR-T cell transformation has been reported to date. Even if T cell transformation occurs, the translatability of a positive result to humans or comparison with a traditional two-year carcinogenicity study in mice is not robust.
The use of animals is predicted to keep increasing with the rapidly expanding research and development programmes on CAR-T therapies for solid tumours and additional indications such as the emerging field of regulatory T cell engineering for autoimmune diseases. For non-oncology indications, the limitations of current in vivo approaches may mean the tumourigenicity risk outweighs the benefit of treatment. An in vitro human based assay that can reliably assess the risk of T cell transformation has the potential to completely replace in vivo studies and improve the assessment of the tumourigenicity potential of modified T cell therapies.
- Nahmad AD., et al., (2022). Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. Nat Biotechnol. https://doi.org/10.1101/2021.08.20.457092
- Micklethwaite, K. et al., (2021). Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood, 138(16), 391-1405. doi: 10.1182/blood.2021010858.
- Bishop, D., et al., (2021). Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. Blood, 138(16), 1504-09. doi: 10.1182/blood.2021010813
- Migone, T., et al., (1995). Constitutively Activated Jak-STAT Pathway in T Cells Transformed with HTLV-I. Science, 269(5220), 79-81. doi: 10.1126/science.7604283
- Akbar, A., et al., (1996). Interleukin-2 receptor common γ-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: Selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. European Journal of Immunology, 26(2), 294-99. doi: 10.1002/eji.1830260204
- D’Souza, W. and Lefrançois, L., (2003). IL-2 Is Not Required for the Initiation of CD8 T Cell Cycling but Sustains Expansion. The Journal of Immunology, 171(11), 5727-35. doi: 10.4049/jimmunol.171.11.5727
- T Hori, et al., (1987) Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood ; 70 (4): 1069–1072. https://doi.org/10.1182/blood.V70.4.1069.1069
- Kees UR, et al., (1991) Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). The American Journal of Pediatric Hematology/oncology. 13(4):459-64. 10.1097/00043426-199124000-00011. Doi: 10.1097/00043426-199124000-00011
- Clinicaltrials.gov. 2022. Home - ClinicalTrials.gov. [online] Available at: <https://clinicaltrials.gov/> [Accessed July 2022].
- Yin, L., et al., (2020). Humanized mouse model: a review on preclinical applications for cancer immunotherapy. American journal of cancer research, 10(12), 4568–84. PMID: 33415020
- Congras A., et al., (2020) ALK-transformed mature T lymphocytes restore early thymus progenitor features. J Clin Invest. Dec 1;130(12):6395-6408. doi: 10.1172/JCI134990
Full Challenge Information
|Professor Ian Kimber (Chair)||University of Manchester|
|Dr Connie Chen (Partner)||HESI|
|Dr Alberto Del Rio (Sponsor)||Gentibio|
|Dr Isabelle Matthiesen (Sponsor)||AstraZeneca|
|Dr Mike Fellows (Sponsor)||AstraZeneca|
|Dr Joana Ferreira (Sponsor)||AstraZeneca|
|Dr Herve Lebrec (Sponsor)||Sonoma Bio|
|Dr Jonathon Clingan (Sponsor)||Sonoma Bio|
|Dr Silvana Libertini (Sponsor)||Novartis|
|Dr George Papadopoulos (Sponsor)||Takeda|
|Dr Kathryn Fraser (Sponsor)||Takeda|
|Dr Hui Ling (Sponsor)||Novartis|
|Professor Mike Capaldi||Newcastle University|
|Professor Mimoun Azzouz||University of Sheffield|
|Professor Gareth Thomas||University of Southampton|
|Professor John Greenman||University of Hull|
|Professor Jan Cools||KU Leuven|
|Dr Sònia Guedan||IDIBAPS Barcelona University Hospital|
|Dr Diana Hernandez||Anthony Nolan|